Recent

% | $
Quotes you view appear here for quick access.

Catalyst Pharmaceutical Partners Inc. Message Board

  • northerntrust@ymail.com northerntrust Nov 25, 2012 1:48 PM Flag

    Upgrade CPRX - Outperform

    On the ratings front, analysts at Rodman & Renshaw upgraded shares of Catalyst Pharmaceutical Partners from a “market perform” rating to an “outperform” rating in a research note to investors. They now have a $3.70 price target on the stock.

    Sentiment: Strong Buy

 
CPRX
3.96+0.02(+0.51%)May 22 4:00 PMEDT